SMN2 and proximal spinal muscular atrophy: As potential approaches for therapeutic strategies against SMA, several investigators have attempted to systemically upregulate the levels of the SMN protein, particularly in the anterior horn cells of the spinal cord [16] However, the spinal cord, which is the target organ in SMA therapy, cannot be sampled for the evaluation of therapeutic efficacy.